WA-SPIE
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005942/en/
SPIE Gold Medal: Michael Berns
In recognition of his work in bioengineering research and his distinguished career that brought together engineers, physicists, biologists, and physicians to collaborate on ground-breaking discoveries and innovations.
SPIE President's Award: Tuan Vo-Dinh
In recognition of his outstanding and extensive role in SPIE conference leadership, in disparate technical areas, and for his mentorship of early investigators as well as peers.
SPIE Directors' Award: Julie Bentley
In recognition of her outstanding service to the Society in extraordinary ways, including authorship, course instruction, conference program leadership, committee membership, and service on the Board of Directors.
SPIE Mozi Award: Thomas W. Ebbesen
In recognition of his phenomenal contributions to the field of nano-optics, especially the extraordinary optical transmission through sub-wavelength hole arrays.
SPIE Britton Chance Award in Biomedical Optics: Bruce Tromberg
In recognition of his high-impact translational research and overall leadership in the development of biophotonic technologies for diagnostics and therapeutics.
SPIE Biophotonics Technology Innovator Award: Bert Müller
In recognition of his distinguished contributions to 2D and 3D imaging for the challenges of the 21st century, including cardiovascular and neurodegenerative diseases, bioinspired dental repair, and incontinence treatment.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Masato Shibuya
In recognition of his significant contributions to the development of optical design through the invention of phase-shift masks for photolithography, and for laying the foundations of imaging theory based on plane-wave expansions.
SPIE Harrison H. Barrett Award in Medical Imaging: Maryellen Giger
In recognition of her pioneering work in the fields of digital image formation, computer-aided diagnosis, radiomics, and radiogenomics.
SPIE Harold E. Edgerton Award in High-Speed Optics: Mona Jarrahi
In recognition of her pioneering contributions to plasmonic time-domain spectroscopy and imaging systems as well as their scientific and industrial applications.
SPIE Dennis Gabor Award in Diffractive Optics: Gabriel Popescu
In recognition of his groundbreaking contributions to holography and quantitative phase imaging for biomedical applications.
SPIE George W. Goddard Award in Space and Airborne Optics: Michelle Stephens
In recognition of her technical innovation, mentoring, and exceptional leadership in pursuit of space-based, fundamental measurements of the Earth and Sun, while reducing technological barriers and promoting standards for the advancement of space and airborne optics.
SPIE G. G. Stokes Award in Optical Polarization: Alex Vitkin
In recognition of his extensive contributions to tissue polarimetry, including advanced methodology developments for sensitive and robust Stokes and Mueller measurements; polarimetric computational and analytical platforms; and biomedical applications including cardiology, regenerative medicine, glucometry, and breast-cancer margin assessment.
SPIE Chandra S. Vikram Award in Optical Metrology: Jürgen Czarske
In recognition of his important contributions to computational laser metrology with paradigm changes in fluid dynamics, inspection, aerospace, communication, and biomedicine.
SPIE Frits Zernike Award for Microlithography: Harry J. Levinson
In recognition of his outstanding achievements contributing to our fundamental understanding of advanced lithography process control, especially in the concepts of Image-Log-Slope, Mask defect printability, and thin-film optics optimization.
SPIE Diversity Outreach Award: Qaisar Abbas Naqvi
In recognition of his inspirational attitude and dedication to students, helping transform the lives of women and men from traditionally under-recognized segments of society by supporting their pursuit of higher education and research in optics and related fields.
SPIE Maria Goeppert-Mayer Award in Photonics: Shin-Tson Wu
In recognition of his seminal contributions to display and photonic device technologies that led to widespread applications.
SPIE Maiman Laser Award: Bill Krupke
In recognition of his scientific, technical and community leadership, innovation, and numerous seminal results in laser science and technology.
SPIE Early Career Achievement Award — Academic Focus: Bhavin Shastri
In recognition of his pioneering efforts in the field of neuromorphic photonics and his contributions to interdisciplinary research across nanophotonics, unconventional computing, and silicon photonics that pushed the frontiers of machine learning.
SPIE Early Career Achievement Award — Industry/Government Focus: Lionel Clermont
In recognition of his significant achievements in the field of stray light control, particularly his work on the development of the ultrafast time-of-flight imaging characterization method.
SPIE Maria J. Yzuel Educator Award: Rajpal Sirohi
In recognition of his many years of service in the field of optics through leadership, capacity building, and outreach.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Ge Wang
In recognition of his pioneering contributions in X-ray and optical molecular tomography, including their coupling for biomedical applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom